Medtech InsightSan Francisco-based Earli is joining the liquid biopsy space with technology that uses cancer’s properties against itself. Since being founded in 2018, the company has raised nearly $60m to develop it
Medtech Insight[ Editor's Note: This daily digest from the J.P. Morgan Healthcare conference has been updated with highlights from Qiagen, Exact Sciences, and Dexcom. ] Baxter Lays Out Three-Part Restructuring Pla
Pink SheetThe US FDA’s approval of Ferring Pharmaceuticals ’ bladder cancer gene therapy Adstiladrin just two weeks after the company took home an approval for the pioneering microbiome therapeutic Rebyota res
ScripMirati Therapeutics, Inc. won accelerated approval from the US Food and Drug Administration for its KRAS G12C inhibitor Krazati (adagrasib) for second-line or later treatment of patients with non-sma